Find your next paid study

University of California, IrvineNCT06028828

Mechanisms of Disease Relapse/Resistance in CAR T Therapy for Hematologic Malignancies

The primary purpose of this IRB protocol is to perform immune profiling focusing on the measurement of Myeloid derived suppressor cells (MDSCs) over time in pa…

Hematologic Malignancy

Duke UniversityNCT05397132

~$10 – $750

A Phase II Trial of Reduced Intensity Fludarabine and Total Body Irradiation-Based Conditioning Prior to Haplo-Identical Transplantation for Patients With Hematologic Malignancies

This trial will evaluate the safety and efficacy of RIC HIDT transplant protocol following fludarabine and intermediate-dose TBI 800 cGy utilizing PBSC as the …

Hematologic Malignancy

Northside Hospital, Inc.NCT05417971

~$10 – $750

Phase 2

Early Use of Tacrolimus in HLA-Mismatched Haploidentical Allogeneic Hematopoietic Transplantation With Post-Transplant Cyclophosphamide

To evalute the safety and efficacy in reducing Cytokine Release Syndrome after hematopoietic stem cell transplantation by introducing immunosuppression earlier…

Hematologic Disease and DisordersHematopoietic Cell Transplant

Northside Hospital, Inc.NCT06828796

Hematologic MalignancyBone Marrow Transplant RejectionAcute Myeloid Leukemia (AML)+9 more

A Pilot Study of Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

This research is being done to investigate the safety and effectiveness of Darzalex Faspro (daratumumab and hyaluronidase-fihj) (a monoclonal antibody that tar…

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06398457

Hematologic MalignancyALL, ChildhoodAML, Childhood+2 more

CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies

The study participant has one of the following blood cancers: acute myelogenous leukemia (AML)/myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (B-…

St. Jude Children's Research HospitalNCT06326463

Phase 2

A Phase II Randomized Trial to Optimize GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation in Older Adults With Hematological Malignancies: the PROMISE Trial

This study will compare post-transplant health-related quality of life following the use of standard versus attenuated dose of post-transplant cyclophosphamide…

Hematological MalignanciesGraft-versus-Host Disease (GVHD)

University of NebraskaNCT06799195

Kidney Failure ChronicStem Cell TransplantStem Cell Transplant Complications+2 more

Addition of Venetoclax to Combined Reduced Intensity Hematopoietic Stem Cell and Kidney Transplantation for Patients With Chronic Kidney Disease and Hematologic Malignancy

The primary objective is to assess the safety of the addition of venetoclax to reduced intensity conditioning for HLA-matched and haploidentical combined HSC a…

Massachusetts General HospitalNCT07358195

A Pilot Prospective Clinical Trial Using Remote Patient Monitoring for Cancer Patients Undergoing Outpatient Chemotherapy

A pilot study using remote monitoring technology developed by Locus Health in cancer patients undergoing chemotherapy treatment.

Solid TumorHematological Malignancy

Inova Health Care ServicesNCT06106360

~$10 – $1,125

Systemic Mastocytosis With an Associated Hematologic Neoplasm

A Phase 1 Study of Avapritinib in Combination With Decitabine in Patients With Systemic Mastocytosis With an Associated Hematologic Neoplasm (SM-AHN)

Systemic mastocytosis with an associated hematologic neoplasm (SM-AHN) is a challenging disease to treat. Targeted KIT inhibitors have been approved for this i…

H. Lee Moffitt Cancer Center and Research InstituteNCT06327685

Advanced Solid TumorsHematologic Malignancies

A Phase 1, Open-Label, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment

This purpose of this study is to help to evaluate the pharmacokinetic (PK) profile of pralatrexate when administered to patients with various degrees of hepati…

Acrotech Biopharma Inc.NCT07036133

~$10 – $8,750

Hematologic MalignancyAMLALL+8 more

A Phase I Study of Tagraxofusp With or Without Chemotherapy in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult pati…